Source: People's Daily - Ningxia Channel
People's Daily Yinchuan, January 20 (Liu Feng, Liang Hongxin) On January 1, 2022, the world's first precision targeted treatment drug for the treatment of spinal muscular atrophy, Nocinasin sodium injection, was included in medical insurance, and the price dropped from nearly 700,000 yuan / needle to 33,000 yuan / needle. On January 19, the People's Hospital of Ningxia Hui Autonomous Region performed nocinnassine sodium injection for the first beneficiary child in Ningxia, bringing new hope to patients and their families.
"Nosinasin sodium" injection. Courtesy of the People's Hospital of the Autonomous Region
It is understood that spinal muscular atrophy (SMA for short) is a rare autosomal recessive genetic disease, caused by the deletion or mutation of the SMN1 gene, mainly manifested as progressive muscle atrophy and weakness, and then the loss of swallowing and respiratory functions. SMA is not uncommon in rare diseases, with an incidence of about 1 in 6000 to 1 in 10000 in newborns, and is the most common fatal hereditary neuromuscular disease in infancy. Before the market of Northinalsan sodium injection, this disease was a situation in which there was no cure, and the treatment measures for SMA in China and worldwide were limited to auxiliary treatment methods such as respiratory support, nutritional support, and orthopedic orthopedics, which brought a heavy burden to families and society. Nocinasin sodium injection is the world's first approved SMA gene shear regulation treatment drug, is an antisense oligonucleotide (ASO), which can change the splicing of SMN2 gene, increase the production of full-length SMN protein, make up for SMN1 expression defects, thereby improving motor function, improving survival rate, and changing the disease progression of SMA.
Injection of "Nocinasine sodium". Courtesy of the People's Hospital of the Autonomous Region
"After the first injection, it is necessary to continue the injection on the 14th, 28th, and 63rd days, and then give a maintenance dose every four months thereafter for a lifetime. The price reduction of drugs and the large proportion of medical insurance reimbursement are undoubtedly the gospel for children with spinal muscular atrophy in Ningxia. Bian Guangbo, director of the Department of Pediatric Neurological Rehabilitation at the People's Hospital of Ningxia Hui Autonomous Region, said.